KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2016 - 2023)

Teva Pharmaceutical Industries (TEVA) has disclosed Short-Term Debt issuances for 11 consecutive years, with $700.0 million as the latest value for Q3 2023.

  • Quarterly Short-Term Debt issuances changed N/A to $700.0 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $700.0 million through Dec 2024, down 22.22% year-over-year, with the annual reading at $700.0 million for FY2023, N/A changed from the prior year.
  • Short-Term Debt issuances for Q3 2023 was $700.0 million at Teva Pharmaceutical Industries, up from $200.0 million in the prior quarter.
  • The five-year high for Short-Term Debt issuances was $700.0 million in Q3 2023, with the low at -$1.0 million in Q1 2019.
  • Average Short-Term Debt issuances over 4 years is $245.6 million, with a median of $200.0 million recorded in 2021.
  • The sharpest move saw Short-Term Debt issuances soared 9900.0% in 2019, then plummeted 37.3% in 2021.
  • Teva Pharmaceutical Industries' Short-Term Debt issuances stood at $404.0 million in 2019, then dropped by 21.04% to $319.0 million in 2020, then crashed by 37.3% to $200.0 million in 2021, then skyrocketed by 250.0% to $700.0 million in 2023.
  • Per Business Quant, the three most recent readings for TEVA's Short-Term Debt issuances are $700.0 million (Q3 2023), $200.0 million (Q4 2021), and $319.0 million (Q4 2020).